It turns out that AbbVie is only interested in buying Gilgamesh's lead drug programme, a psychedelic candidate for major ...

Nucleus RadioPharma, the radiopharmaceutical-focused contract developing and manufacturing organisation founded by Eclipse ...

A new study published in the Nature journal of Mental Health Research shows powerful real-world evidence for the efficacy of ...

Despite being a rare disease impacting less than a million people worldwide, gMG treatment is an increasingly crowded market, ...

Concern about the safety of gene therapies has been thrust into the spotlight again with the news that two patients treated with Novartis' spinal muscular atrophy (SMA) treatment Zolgensma died as ...

Plasticell, a developer of cell therapies including hematopoietic cell replacement therapies, has secured £920,000 from the British government’s Innovate UK to create a safe, effective red ...

The FDA has declined to approve two more cancer therapies developed by drugmakers based in China, in what may be further evidence of a tough line taken by the regulator for drugs tested outside ...

Developing treatments for rare diseases poses many unique challenges that cannot be addressed by traditional study designs.

Gilead's Kite unit has reached an agreement to buy Interius BioTherapeutics, boosting its in vivo cell therapy credentials.

Hundreds of current and former workers at the Department of Health and Human Services (HHS) have penned a letter to Robert F Kennedy Jr, asking him to stop spreading misinformation that is ...

Targovax interviewed by pharmaphorum said the market for oncolytic viruses is set to get increasingly crowded in the future as pharma tries to use the approach to improve efficacy of checkpoint ...

Sanofi is to acquire UK biotech Kymab in a deal worth up to $1.45 billion as the big French pharma seeks to add to its pipeline of drugs that treat inflammatory diseases and cancer. Cambridge ...